AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9169179 — intervention group
Group type: COMPARATOR
Intervention: Fertile women (control group)
Number of subjects: 413
Study 8458113 — intervention group
Group type: EXPERIMENTAL
Intervention: fosinopril 10 mg
Number of subjects: 64
Study 8458113 — intervention group
Group type: EXPERIMENTAL
Intervention: fosinopril 20 mg
Number of subjects: 64
Study 8458113 — intervention group
Group type: EXPERIMENTAL
Intervention: fosinopril 40 mg
Number of subjects: 64
Study 8458113 — intervention group
Group type: EXPERIMENTAL
Intervention: fosinopril (all dosages)
Number of subjects: 64
Study 8458113 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 3532972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter-saving resection
Number of subjects: 413
Study 3532972 — intervention group
Group type: COMPARATOR
Intervention: Abdominoperineal resection
Number of subjects: 413
Study 28238045 — intervention group
Group type: EXPERIMENTAL
Intervention: AIPCW estimator
Number of subjects: 0
Study 28238045 — intervention group
Group type: EXPERIMENTAL
Intervention: Three anti-HIV regimens
Number of subjects: 0
Study 26654751 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (CAFAP)
Number of subjects: 56
Study 24402825 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized curcumin (500 mg)
Number of subjects: 23
Study 24402825 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid micellar curcumin (500 mg)
Number of subjects: 23
Study 24402825 — intervention group
Group type: COMPARATOR
Intervention: Native curcumin (500 mg)
Number of subjects: 23
Study 22039932 — intervention group
Group type: EXPERIMENTAL
Intervention: Coeliac School educational programme (n = 54)
Number of subjects: 106
Study 22039932 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 52)
Number of subjects: 106
Study 20022464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 77
Study 20022464 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 77
Study 18554243 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha tailored treatment (5 million units thrice weekly for a median of 10 months, range 6-24 months)
Number of subjects: 374
Study 18554243 — intervention group
Group type: COMPARATOR
Intervention: Control group (Interferon-alpha 5 million units thrice weekly for 6 months)
Number of subjects: 374
Study 15782295 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa-IPV (Boostrix Polio)
Number of subjects: 770
Study 15782295 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV (Infanrix IPV)
Number of subjects: 770
Study 15782295 — intervention group
Group type: COMPARATOR
Intervention: dTpa + IPV (Boostrix + Imovax Polio)
Number of subjects: 770
Study 11487307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate (225.5 mg), twice a day for 1 week
Number of subjects: 10
Study 11487307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9596003 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000-lux light for 60 minutes
Number of subjects: 7
Study 9596003 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (self-regulated eye opening)
Number of subjects: 7
Study 7810780 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 36
Study 7810780 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (Group I)
Number of subjects: 36
Study 2902813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.01 mg/kg) after lormetazepam (0.06 mg/kg)
Number of subjects: 18
Study 2902813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.01 mg/kg) after flunitrazepam (0.03 mg/kg)
Number of subjects: 18
Study 2902813 — intervention group
Group type: COMPARATOR
Intervention: Ro 15‐1788 (0.01 mg/kg) after placebo
Number of subjects: 18
Study 1392698 — intervention group
Group type: COMPARATOR
Intervention: Cyclical estrogen-progestagen replacement treatment
Number of subjects: 36
Study 1392698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate
Number of subjects: 36
Study 1392698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Cyclical estrogen-progestagen replacement treatment and Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate)
Number of subjects: 36
Study 637286 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 0
Study 637286 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia
Number of subjects: 0
Study 637286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture-analgesia
Number of subjects: 0
Study 31071541 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial for preschool onset depression
Number of subjects: 35
Study 31071541 — intervention group
Group type: COMPARATOR
Intervention: Community-recruited children
Number of subjects: 35
Study 28890922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted Classroom (IC) method
Number of subjects: 299
Study 28890922 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method (control)
Number of subjects: 299
Study 26007680 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP-TMDs
Number of subjects: 76
Study 23509019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 200 μg
Number of subjects: 160
Study 23509019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 μg
Number of subjects: 160
Study 23509019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23509019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl (both doses)
Number of subjects: 160
Study 21890580 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring (8.3 mm thick vinyl floor covering with polyvinyl chloride foam backing)
Number of subjects: 0
Study 21890580 — intervention group
Group type: COMPARATOR
Intervention: Standard flooring (control group)
Number of subjects: 0
Study 21890580 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring
Number of subjects: 0
Study 19648781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% retinol (ROL)
Number of subjects: 48
Study 19648781 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ROL-containing product
Number of subjects: 48
Study 19648781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan fluorescence spectroscopy in active-agent-treated group
Number of subjects: 48
Study 19648781 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 17341509 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust mobilization/manipulation
Number of subjects: 60
Study 17341509 — intervention group
Group type: COMPARATOR
Intervention: Thoracic spine nonthrust mobilization/manipulation
Number of subjects: 60
Study 15461622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m2
Number of subjects: 54
Study 15461622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Number of subjects: 54
Study 15461622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib alone or in combination with dexamethasone
Number of subjects: 54
Study 15461622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 54
Study 11916359 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg (n = 85)
Number of subjects: 176
Study 11916359 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg (n = 91)
Number of subjects: 176
Study 9773694 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 1874
Study 9773694 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1874
Study 7848395 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every day
Number of subjects: 34
Study 7848395 — intervention group
Group type: COMPARATOR
Intervention: H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)
Number of subjects: 34
Study 2904881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 2904881 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 2904881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with severe hypoglycemic episodes
Number of subjects: 0
Study 30517065 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5% hydrogen peroxide (HP) gel
Number of subjects: 33
Study 30517065 — intervention group
Group type: COMPARATOR
Intervention: 6% hydrogen peroxide (HP) gel
Number of subjects: 33
Study 30517065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (37.5% HP and 6% HP)
Number of subjects: 33
Study 28448087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean type diet (DIET) for 16 weeks
Number of subjects: 99
Study 28448087 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (CON)
Number of subjects: 99
Study 25581251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 1320
Study 25581251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1320
Study 23179176 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD spray (2 sprays: 5.4 mg THC and 5.0 mg CBD, 4 sprays: 10.8 mg THC and 10.0 mg CBD, 8 sprays: 21.6 mg THC and 20.0 mg CBD)
Number of subjects: 0
Study 23179176 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD spray (multiple doses: 2, 4, or 8 sprays once daily for nine consecutive days)
Number of subjects: 0
Study 21526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg of colostrum protein taken thrice daily with bicarbonate buffer
Number of subjects: 90
Study 21526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg colostrum protein given with buffer
Number of subjects: 90
Study 21526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 400 mg colostrum protein given without buffer
Number of subjects: 90
Study 21526980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 200 mg colostrum protein given without buffer
Number of subjects: 90
Study 21526980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18834057 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning as a teaching strategy
Number of subjects: 0
Study 16492716 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz electrical stimuli
Number of subjects: 8
Study 16492716 — intervention group
Group type: COMPARATOR
Intervention: 0.1 Hz electrical stimuli
Number of subjects: 8
Study 14632250 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCABG (off-pump CABG)
Number of subjects: 43
Study 14632250 — intervention group
Group type: COMPARATOR
Intervention: CPB CABG (CABG with cardiopulmonary bypass)
Number of subjects: 43
Study 11702833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical vacuum cap cannula
Number of subjects: 50
Study 11702833 — intervention group
Group type: COMPARATOR
Intervention: Metal cannula
Number of subjects: 50
Study 9692538 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile women (n=47)
Number of subjects: 47
Study 9692538 — intervention group
Group type: COMPARATOR
Intervention: Fertile controls (n=47)
Number of subjects: 47
Study 7834164 — intervention group
Group type: COMPARATOR
Intervention: Controlled release dosage form of sodium monofluoro phosphate (NaMFP) at a dose of 160 mg, with a drug to polymer ratio of 1:1.1, delivered over 6 hours.
Number of subjects: 0
Study 7834164 — intervention group
Group type: COMPARATOR
Intervention: Immediate release dosage form of sodium monofluoro phosphate (NaMFP) used as a control in a two‐period crossover study.
Number of subjects: 0
Study 2968885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime ultralente administration
Number of subjects: 10
Study 2968885 — intervention group
Group type: COMPARATOR
Intervention: Morning ultralente administration
Number of subjects: 10
Study 2968885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (bedtime and morning)
Number of subjects: 10
Study 31149709 — intervention group
Group type: EXPERIMENTAL
Intervention: l-leucine supplementation (7.5 g·d‐1) with resistance training (3 times/week)
Number of subjects: 19
Study 31149709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (l-alanine) with resistance training (3 times/week)
Number of subjects: 19
Study 31149709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (l-leucine and l-alanine)
Number of subjects: 19
Study 27571766 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Visual Awareness (AVA) test in PTV
Number of subjects: 70
Study 27571766 — intervention group
Group type: COMPARATOR
Intervention: Assessment of Visual Awareness (AVA) test in STV
Number of subjects: 70
Study 25563714 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg orally once a week for 3 months)
Number of subjects: 72
Study 25563714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (treatment as usual)
Number of subjects: 72
Study 22801943 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily exercise until discharge home and twice weekly as outpatient for 8 weeks
Number of subjects: 15
Study 22801943 — intervention group
Group type: COMPARATOR
Intervention: Control arm received protocolized inpatient respiratory physiotherapy
Number of subjects: 15
Study 20199815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)
Number of subjects: 57
Study 20199815 — intervention group
Group type: COMPARATOR
Intervention: Control group without IV treatment before PCI
Number of subjects: 57
Study 19246447 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mg nicotine patch for 6 months
Number of subjects: 20
Study 17105759 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI and stenting with optimal medical therapy
Number of subjects: 2166
Study 17105759 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2166
Study 15589713 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 15589713 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study 11759140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (high bupivacaine)
Number of subjects: 68
Study 11759140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (high ropivacaine)
Number of subjects: 68
Study 11759140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (low bupivacaine)
Number of subjects: 68
Study 11759140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine (low ropivacaine)
Number of subjects: 68
Study 11759140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% study drug infusion with 0.6 microgram/mL of sufentanil
Number of subjects: 68
Study 9359507 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensification at 5 weeks
Number of subjects: 618
Study 9359507 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification at 20 weeks
Number of subjects: 618
Study 9359507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and late intensification
Number of subjects: 618
Study 9359507 — intervention group
Group type: COMPARATOR
Intervention: Neither early nor late intensification
Number of subjects: 618
Study 8259774 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B 20 micrograms
Number of subjects: 460
Study 8259774 — intervention group
Group type: COMPARATOR
Intervention: Recombivax HB 10 micrograms
Number of subjects: 460
Study 2939871 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42
Study 2939871 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study 27817096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 552
Study 27817096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 552
Study 27719705 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Number of subjects: 30
Study 27719705 — intervention group
Group type: COMPARATOR
Intervention: Apically repositioned flap
Number of subjects: 30
Study 24667461 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and insulin during normoglycemic-hyperinsulinemic clamp
Number of subjects: 2
Study 24667461 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 during normoglycemic-normoinsulinemic clamp
Number of subjects: 2
Study 24667461 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and insulin during normoglycemia
Number of subjects: 2
Study 24667461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic-hyperinsulinemic clamp with GLP-1
Number of subjects: 2
Study 24667461 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemic-normoinsulinemic clamp
Number of subjects: 2
Study 22148879 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years BASIC parent training program (IYBP)
Number of subjects: 149
Study 22148879 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 149
Study 20124563 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 752
Study 20124563 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly
Number of subjects: 752
Study 20124563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 752
Study 17823565 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV (pressure support level, 12 cmH2O; positive end-expiratory pressure, 5 cmH2O; FiO2, 0.6)
Number of subjects: 23
Study 17823565 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (oxygen 8 l/min via Venturi face mask)
Number of subjects: 23
Study 16207770 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational processes influencing risk assessment
Number of subjects: 0
Study 16207770 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to the present partner
Number of subjects: 0
Study 11915588 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Number of subjects: 28
Study 11915588 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg
Number of subjects: 28
Study 9895083 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (IV bolus of 0.7 mg/kg followed by a constant infusion of 0.15 mg x kg(‐1) x h(‐1))
Number of subjects: 20
Study 9895083 — intervention group
Group type: COMPARATOR
Intervention: Saline (equal volume administered)
Number of subjects: 20
Study 10481503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser therapy
Number of subjects: 32
Study 10481503 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 32
Study 1830287 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 1830287 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine/Mefruside combination
Number of subjects: 0
Study 6661343 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment for 2 weeks
Number of subjects: 18
Study 6661343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole treatment after timolol
Number of subjects: 18
Study 31502232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth) among those with low levels of grade attainment
Number of subjects: 0
Study 31502232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth) among those with higher levels of grade attainment
Number of subjects: 0
Study 31502232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent childbearing (first birth)
Number of subjects: 0
Study 29205909 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPA-treatment (sedentary behavior)
Number of subjects: 52
Study 29205909 — intervention group
Group type: COMPARATOR
Intervention: HAPA-control (nutrition)
Number of subjects: 52
Study 28848898 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 or 27.5/31.2 µg twice daily (b.i.d.)
Number of subjects: 85
Study 28848898 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol (IND) 75 µg once daily (o.d.)
Number of subjects: 85
Study 24281848 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stress measured using the Parenting Stress Index, short form.
Number of subjects: 106
Study 24281848 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stress measured prior to depression diagnosis.
Number of subjects: 106
Study 22093775 — intervention group
Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy for 12 weeks followed by LHRH agonist (leuprolide or goserelin) for 8 weeks
Number of subjects: 176
Study 22093775 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist therapy (leuprolide or goserelin)
Number of subjects: 176
Study 22093775 — intervention group
Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy
Number of subjects: 176
Study 22093775 — intervention group
Group type: EXPERIMENTAL
Intervention: Abarelix initiation therapy and LHRH agonist maintenance therapy
Number of subjects: 176
Study 20361916 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/d
Number of subjects: 0
Study 20361916 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg/d
Number of subjects: 0
Study 20361916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18771988 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversal expansion
Number of subjects: 811
Study 18771988 — intervention group
Group type: COMPARATOR
Intervention: Cephalad-caudad expansion
Number of subjects: 811
Study 16183466 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based intervention
Number of subjects: 228
Study 16183466 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 228
Study 12202435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue ICSI of unfertilized oocytes (group I; n = 120)
Number of subjects: 400
Study 12202435 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICSI cycles; group II; n = 280)
Number of subjects: 400
Study 10404423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoasca (2 ml/kg body weight)
Number of subjects: 15